Did the PTC Therapeutics insider receive cash from this 867-share transaction?

No. The transaction is coded as a gift with a reported price of $0 per share, indicating that the reporting person did not receive cash proceeds from this transfer.

PTCT insider Form 4: director donates 867 common shares

Q: What insider transaction did PTC Therapeutics (PTCT) report in this Form 4?

The Form 4 reports that a director of PTC Therapeutics, Inc. (PTCT) made a bona fide gift of 867 shares of the company’s common stock to a charitable organization on 11/20/2025.

Q: What is the relationship of the reporting person to PTC Therapeutics?

The reporting person is identified as a Director of PTC Therapeutics, Inc., with the Form 4 indicating the filing is made by one reporting person.

Q: What does the Form 4 explanation say about the PTC Therapeutics stock transfer?

The explanation states that the transaction represents the reporting person's bona fide gift of shares of the issuer's common stock to a charitable organization.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

PTC Therapeutics director reports charitable stock gift

A director of PTC Therapeutics, Inc. (PTCT) reported a bona fide gift of 867 shares of the company’s common stock on 11/20/2025. The transaction was coded as a gift and priced at $0, reflecting that no sale proceeds were received. After this transaction, the reporting person beneficially owns 8,000 shares of PTC Therapeutics common stock in direct ownership. The filing is made on Form 4 for a single reporting person and indicates the shares were donated to a charitable organization.

Insider Trade Summary

Net Seller: 867 shares

Net Sell 1 txn

Insider Okey Stephanie

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	867	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,000 shares (Direct)

Footnotes (1)

F1. Represents the Reporting Person's bona fide gift of shares of the issuer's common stock to a charitable organization.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report in this Form 4?

The Form 4 reports that a director of PTC Therapeutics, Inc. (PTCT) made a bona fide gift of 867 shares of the company’s common stock to a charitable organization on 11/20/2025.

How many PTC Therapeutics (PTCT) shares does the director own after the gift?

Following the reported gift of 867 shares, the director beneficially owns 8,000 shares of PTC Therapeutics common stock, held in direct ownership.

What is the relationship of the reporting person to PTC Therapeutics?

The reporting person is identified as a Director of PTC Therapeutics, Inc., with the Form 4 indicating the filing is made by one reporting person.

What does the Form 4 explanation say about the PTC Therapeutics stock transfer?

The explanation states that the transaction represents the reporting person's bona fide gift of shares of the issuer's common stock to a charitable organization.

Were any derivative securities reported in this PTC Therapeutics Form 4?

No derivative securities were listed as acquired, disposed of, or beneficially owned in Table II of this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/21/2025 - 05:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Okey Stephanie

(Last)

(First)

(Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN

07059

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/20/2025		G⁽¹⁾		867	D	$0	8,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the Reporting Person's bona fide gift of shares of the issuer's common stock to a charitable organization.

	/s/ Avraham S. Adler, Attorney-in-Fact	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR